Inventor · disambiguated record
Brigitte Devaux
Also filed as: DEVAUX BRIGITTE
32 granted patents·18 pending applications·942 citations·filing 1999–2025
97Inventor score
Top patents by PatentIndex Score
50 records- 0198US7615383B2Methods for treating neuropathy by agonist anti-trk-C monoclonal antibodiesGENENTECH INC·Filed 2006·Granted Nov 10, 2009·99 cites·19 claims
- 0297US10189902B2Antibodies to TIGITBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 29, 2019·27 cites·8 claims
- 0397US7960515B2Binding molecules to the human OX40 receptorBRISTOL MYERS SQUIBB CO·Filed 2008·Granted Jun 14, 2011·205 cites·12 claims
- 0497US7384632B2Agonist anti-trk-C monoclonal antibodiesGENENTECH INC·Filed 2001·Granted Jun 10, 2008·86 cites·2 claims
- 0596US8236930B2Binding molecules to the human OX40 receptorMIN JING·Filed 2011·Granted Aug 7, 2012·85 cites·5 claims
- 0696US6824780B1Anti-tumor antibody compositions and methods of useGENENTECH INC·Filed 2000·Granted Nov 30, 2004·264 cites·9 claims
- 0795US9028824B2Binding molecules to the human OX40 receptorMIN JING·Filed 2012·Granted May 12, 2015·75 cites·22 claims
- 0894US12312403B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Granted May 27, 2025·1 cites·17 claims
- 0994US10077306B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 18, 2018·7 cites·22 claims
- 1093US10533052B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 14, 2020·4 cites·30 claims
- 1193US9683998B2Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereofPFIZER·Filed 2014·Granted Jun 20, 2017·32 cites·13 claims
- 1290US11474112B2Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereofPFIZER·Filed 2019·Granted Oct 18, 2022·4 cites·27 claims
- 1388US7435416B2Anti-tumor antibody compositions and methods of useGENENTECH INC·Filed 2004·Granted Oct 14, 2008·18 cites·7 claims
- 1487US10479838B2Antibodies to CD40 with enhanced agonist activityUNIV ROCKEFELLER·Filed 2016·Granted Nov 19, 2019·7 cites·10 claims
- 1587US2024209083A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 1686US11591392B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 28, 2023·1 cites·19 claims
- 1784US2024336695A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1883US11008390B2Antibodies to TIGITBRISTOL MYERS SQUIBB CO·Filed 2018·Granted May 18, 2021·2 cites·16 claims
- 1982US8039596B2Alpha 5-beta 1 antibodies and their usesBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Oct 18, 2011·4 cites·10 claims
- 2079US12372536B2Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereofPFIZER·Filed 2022·Granted Jul 29, 2025·0 cites·30 claims
- 2179US8188235B2Antibodies to IL-6 and their usesRAJPAL ARVIND·Filed 2009·Granted May 29, 2012·3 cites·10 claims
- 2278US11306149B2Anti-CD40 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 19, 2022·1 cites·20 claims
- 2378US10196452B2Binding molecules to the human OX40 receptorPFIZER·Filed 2017·Granted Feb 5, 2019·1 cites·16 claims
- 2478US2024174749A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2577US7354585B2Methods of treating coagulapathic or thrombotic disordersGENENTECH INC·Filed 2006·Granted Apr 8, 2008·2 cites·15 claims
- 2676US2025326841A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 2776US2022002428A1Binding molecules to the human ox40 receptorPFIZER·Filed 2021·Application pending·0 cites
- 2876US2025115664A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2974US11952427B2Anti-CD40 antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Apr 9, 2024·0 cites·20 claims
- 3070US12060421B2Antibodies to TIGITBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Aug 13, 2024·0 cites·6 claims
- 3168US2025197494A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 3268US2021054091A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3367US10844130B2Nucleic acids encoding an anti-CD40 antibodyBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 24, 2020·0 cites·16 claims
- 3467US2019135932A1Binding molecules to the human ox40 receptorPFIZER·Filed 2019·Application pending·0 cites
- 3567US2010003261A1agonist anti-trk-c monoclonal antibodiesDEVAUX BRIGITTE·Filed 2009·Application pending·0 cites
- 3662US12129297B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 29, 2024·0 cites·10 claims
- 3762US6624295B1Human anti-factor IX/IXa antibodiesGENENTECH INC·Filed 1999·Granted Sep 23, 2003·14 cites·8 claims
- 3862US2015203574A1Antibodies to il-6 and their usesPFIZER·Filed 2014·Application pending·0 cites
- 3961US8846037B2Antibodies to IL-6 and their usesPFIZER·Filed 2013·Granted Sep 30, 2014·0 cites·33 claims
- 4061US2021363242A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 4159US9840562B2Binding molecules to the human OX40 receptorPFIZER·Filed 2015·Granted Dec 12, 2017·0 cites·24 claims
- 4259US2018142030A1Antibodies to cd40BRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 4357US8436158B2Antibodies to IL-6 and their usesRAJPAL ARVIND·Filed 2012·Granted May 7, 2013·0 cites·39 claims
- 4455US7049411B2Human anti-factor IX/IXa antibodiesGENENTECH INC·Filed 2003·Granted May 23, 2006·0 cites·20 claims
- 4555US2018052175A1Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereofPFIZER·Filed 2017·Application pending·0 cites
- 4655US2012045443A1Agonist anti-trk-c monoclonal antibodiesDEVAUX BRIGITTE·Filed 2011·Application pending·0 cites
- 4754US2014154268A1Alpha5-beta1 antibodies and their usesPFIZER·Filed 2013·Application pending·0 cites
- 4852US2020071412A1Antibodies to cd40 with enhanced agonist activityUNIV ROCKEFELLER·Filed 2019·Application pending·0 cites
- 4949US8399647B2Alpha5-beta1 antibodies and their usesBENDER STEVEN L·Filed 2011·Granted Mar 19, 2013·0 cites·8 claims
- 5049US2004005598A1PUMPCn compositions and uses thereofGENENTECH INC·Filed 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →